Aptose Biosciences (NASDAQ:APTO) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report issued to clients and investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th.

Aptose Biosciences Trading Down 13.8 %

NASDAQ APTO opened at $0.18 on Monday. Aptose Biosciences has a 12 month low of $0.13 and a 12 month high of $2.08. The stock has a 50 day moving average of $0.21 and a 200-day moving average of $0.32. The company has a market cap of $10.83 million, a PE ratio of -0.06 and a beta of 0.88.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its holdings in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent reporting period. Institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.